S. Syddall

Most-cited papers

1. Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104

   A. Patterson, D. M. Ferry, S. Edmunds, Yong-Chuan Gu +9 more

   2007Clinical Cancer Research230 citations Open access

   Semantic Scholar

   Save

2. Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy

   G. Dachs, Michelle A. Hunt, S. Syddall, Dean C. Singleton +1 more

   2009Molecules113 citations Open access

   Semantic Scholar

   Save

3. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.

   G. A. Prosser, J. Copp, A. Mowday, C. Guise +9 more

   2013Biochemical Pharmacology57 citations

   Semantic Scholar

   Save

4. Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators

   W. Wilson, S. Stribbling, F. Pruijn, S. Syddall +5 more

   2009Molecular Cancer Therapeutics32 citations

   Semantic Scholar

   Save

5. Comparison of open and closed suction on safety, efficacy and nursing time in a paediatric intensive care unit.

   Janine Evans, S. Syddall, W. Butt, S. Kinney

   2014Australian Critical Care28 citations

   Semantic Scholar

   Save

6. E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications

   A. Mowday, J. Copp, S. Syddall, L. Dubois +12 more

   2020Theranostics26 citations Open access

   Semantic Scholar

   Save

7. Pseudomonas aeruginosa NfsB and nitro-CBI-DEI – a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy

   L. K. Green, S. Syddall, K. M. Carlin, Glenn D Bell +6 more

   2013Molecular Cancer18 citations Open access

   Semantic Scholar

   Save

8. Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit

   Dean C. Singleton, A. Mowday, C. Guise, S. Syddall +6 more

   2021Cancer Gene Therapy8 citations

   Semantic Scholar

   Save

9. Abstract B76: Cellular metabolism, murine pharmacokinetics and preclinical antitumor activity of SN29966, a novel hypoxia‐activated irreversible pan‐HER inhibitor

   A. Patterson, Jagdish Jaswail, S. Syddall, M. Abbattista +11 more

   20098 citations

   Semantic Scholar

   Save

10. Abstract A247: Mechanism of action of the hypoxia-activated irreversible pan-HER inhibitor SN29966.

    J. Smaill, J. Jaiswal, M. Abbattista, Guo-Liang Lu +16 more

    20115 citations

    Semantic Scholar

    Save

11. Abstract C46: Design and identification of the novel hypoxia‐activated irreversible pan‐HER inhibitor SN29966

    J. Smaill, Guo-Liang Lu, W. V. van Leeuwen, M. Abbattista +9 more

    20094 citations

    Semantic Scholar

    Save

12. Comparison of open versus closed endotracheal suction in a paediatric intensive care unit

    Janine Evans, S. Syddall

    20130 citations

    Semantic Scholar

    Save

13. Abstract B88: Discovery, characterization, and engineering of bacterial nitroreductases for gene-directed enzyme prodrug therapy.

    D. Ackerley, J. Copp, E. Williams, A. Mowday +5 more

    20110 citations

    Semantic Scholar

    Save

14. Abstract B89: Molecular imaging using bacterial nitroreductase reporter genes by repurposing the clinical stage hypoxia PET probe EF5.

    A. Patterson, J. Copp, S. Syddall, C. Guise +9 more

    20110 citations

    Semantic Scholar

    Save

15. Abstract LB-297: Characterization of novel hypoxia-activated prodrugs of irreversible pan-HER inhibitors

    Guo-Liang Lu, J. Smaill, Maria Abbattisia, R. Anderson +15 more

    20100 citations

    Semantic Scholar

    Save

16. 300 POSTER Oncolytic adenovirus ONYX-411NTR enhances the antitumour efficacy of the bioreductive alkylator prodrug PR-104

    Dean C. Singleton, S. Syddall, S.-Y. Bai, Dan Li +3 more

    20080 citations

    Semantic Scholar

    Save